Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Alcohol septal ablation in patients with severe septal hypertrophy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Interaction of ischaemic postconditioning and thrombectomy in patients with ST-elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Significantly increased risk of all-cause mortality among cardiac patients feeling lonely

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Role of the lymphatic vasculature in cardiovascular medicine

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical usefulness of FDG-PET/CT for identification of abnormal extra-cardiac foci in patients with infective endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Amyloid transthyretinkardiomyopati

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Screening relatives in arrhythmogenic right ventricular cardiomyopathy: yield of imaging and electrical investigations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking. Therefore, we analysed patients in the Euro-ASA registry to test this statement.

METHODS: We compared the short-term and long-term outcomes of patients with basal interventricular septum (IVS) thickness <30 mm Hg to those with ≥30 mm Hg treated using ASA in nine European centres.

RESULTS: A total of 1519 patients (57±14 years, 49% women) with symptomatic HOCM were treated, including 67 (4.4%) patients with IVS thickness ≥30 mm. The occurrence of short-term major adverse events were similar in both groups. The mean follow-up was 5.4±4.3 years and 5.1±4.1 years, and the all-cause mortality rate was 2.57 and 2.94 deaths per 100 person-years of follow-up in the IVS <30 mm group and the IVS ≥30 mm group (p=0.047), respectively. There were no differences in dyspnoea (New York Heart Association class III/IV 12% vs 16%), residual left ventricular outflow tract gradient (16±20 vs 16±16 mm Hg) and repeated septal reduction procedures (12% vs 18%) in the IVS <30 mm group and IVS ≥30 mm group, respectively (p=NS for all).

CONCLUSIONS: The short-term results and the long-term relief of dyspnoea, residual left ventricular outflow obstruction and occurrence of repeated septal reduction procedures in patients with basal IVS ≥30 mm is similar to those with IVS <30mm. However, long-term all-cause and cardiac mortality rates are worse in the ≥30 mm group.

OriginalsprogEngelsk
TidsskriftHeart (British Cardiac Society)
Vol/bind106
Udgave nummer6
Sider (fra-til)462-466
Antal sider5
ISSN1355-6037
DOI
StatusUdgivet - mar. 2020

ID: 58015341